AMGEN INC (AMGN) — SEC Filings

Latest SEC filings for AMGEN INC (AMGN), explained in plain English.

Sentiment Overview: 2 bullish, 28 neutral

Recent Filings (30)

• Amgen Files 2025 Annual Report to Security Holders — ARS · 2026-03-31T09:00:13-04:00 [neutral] Risk: low
  Amgen Inc. filed its Annual Report to Security Holders (ARS) on March 31, 2026, for the period ending December 31, 2025. The report details the company's financ
• Amgen's Q3 Earnings Soar on Strong Product Sales, R&D Spikes — 10-Q · 2025-11-05T00:00:00.000Z [bullish] Risk: medium
  Amgen Inc. reported robust financial performance for the three and nine months ended September 30, 2025. Total revenues increased by 12.4% to $9.557 billion for
• 8-K Filing — 8-K · 2025-11-04T00:00:00.000Z [neutral]
• Amgen Q2 Sales Climb on Strong Product Demand — 10-Q · 2025-08-06T00:00:00.000Z [bullish] Risk: medium
  AMGEN INC reported product sales of $6.85 billion for the second quarter of 2025, an increase from $6.50 billion in the second quarter of 2024. Total revenues f
• Amgen Files 8-K on Financials and Exhibits — 8-K · 2025-08-05T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. The
• Amgen Inc. Files 8-K for Security Holder Vote — 8-K · 2025-05-27T00:00:00.000Z [neutral] Risk: low
  On May 23, 2025, Amgen Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not disclose specific det
• Amgen Q1 2025 Update: Financials and Product Performance — 10-Q · 2025-05-02T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial statements include details on common stock, A2.
• Amgen Inc. Files 8-K on Financials — 8-K · 2025-05-01T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. filed an 8-K on May 1, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. The fil
• Amgen Inc. Files Definitive Proxy Materials — DEFA14A · 2025-04-29T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. filed a Definitive Additional Materials proxy statement on April 29, 2025. This filing is related to the company's proxy statement and is not a preli
• Amgen Files Definitive Proxy Materials — DEFA14A · 2025-04-17T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. filed a Definitive Additional Materials proxy statement on April 17, 2025. This filing is related to the company's annual meeting and is not a prelim
• Amgen Inc. DEF 14A: Executive Compensation Details — DEF 14A · 2025-04-09T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. filed its DEF 14A on April 9, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on
• Amgen Files 2024 10-K: Financials and Operations Detailed — 10-K · 2025-02-14T00:00:00.000Z [neutral] Risk: medium
  Amgen Inc. filed its 2024 10-K on February 14, 2025, detailing its fiscal year ending December 31, 2024. The company, a leader in biological products, is headqu
• Amgen Inc. Files 8-K on Financials — 8-K · 2025-02-04T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. filed an 8-K on February 4, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
• Amgen Inc. Q3 2024 Results Filed — 10-Q · 2024-10-31T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. reported its third-quarter results for the period ending September 30, 2024. The company's filing indicates financial activities and product sales fo
• Amgen Inc. Files 8-K on Financials — 8-K · 2024-10-30T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. filed an 8-K on October 30, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The f
• SC 13G/A Filing — SC 13G/A · 2024-08-23T00:00:00.000Z [neutral]
• Amgen Inc. Files 10-Q for Q2 2024 — 10-Q · 2024-08-07T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's financial statements and business operations are detailed in this 10-Q
• Amgen Inc. Files 8-K for Operations and Financials — 8-K · 2024-08-06T00:00:00.000Z [neutral] Risk: low
  On August 6, 2024, Amgen Inc. filed an 8-K report to disclose information regarding its results of operations and financial condition, as well as financial stat
• Amgen Inc. Announces Board Changes and Executive Appointments — 8-K · 2024-06-03T00:00:00.000Z [neutral] Risk: low
  On May 31, 2024, Amgen Inc. filed an 8-K report detailing the departure of director Robert Bradway and the election of new directors, including David E.I. Pyott
• Amgen Files Proxy Statement for Annual Meeting — DEFA14A · 2024-05-10T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. filed a Definitive Proxy Statement (DEFA14A) on May 10, 2024, for its annual shareholder meeting. The filing details the company's governance, execut
• Amgen Files Proxy Statement for Annual Meeting — DEFA14A · 2024-05-03T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. filed its definitive proxy statement (DEFA14A) on May 3, 2024, for its upcoming annual meeting. The filing details the company's governance, executiv
• Amgen Q1 2024 Financials: Product Sales and Balance Sheet Details — 10-Q · 2024-05-03T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. reported its first quarter 2024 results for the period ending March 31, 2024. The company's filing details its financial performance, including produ
• Amgen Inc. Files 8-K on Financials — 8-K · 2024-05-02T00:00:00.000Z [neutral] Risk: low
  On May 2, 2024, Amgen Inc. filed an 8-K report detailing its financial results and condition. The filing includes financial statements and exhibits related to i
• Amgen Files Proxy Statement for Shareholder Meeting — DEFA14A · 2024-04-26T00:00:00.000Z [neutral] Risk: low
  Amgen Inc. filed a Definitive Proxy Statement (DEFA14A) on April 26, 2024, for its annual shareholder meeting. The filing outlines the company's governance, exe
• Amgen Inc. DEF 14A: Executive Compensation Details Revealed — DEF 14A · 2024-04-17T00:00:00.000Z [neutral] Risk: medium
  Amgen Inc. filed its DEF 14A on April 17, 2024, detailing executive compensation for the fiscal year ending December 31, 2023. The filing includes information o
• Amgen Files 2023 Annual Report, Details Fiscal Year End — 10-K · 2024-02-14T00:00:00.000Z [neutral] Risk: medium
  AMGEN INC filed its 10-K report on February 14, 2024, for the fiscal year ended December 31, 2023. The filing, identified by CIK 0000318154, details the company
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• AMGEN FILES 8-K ON FINANCIAL RESULTS, EXHIBITS — 8-K · 2024-02-06T00:00:00.000Z [neutral]
  Amgen Inc. filed an 8-K on February 6, 2024, to report its results of operations and financial condition, along with related financial statements and exhibits.
• State Street Corp. Updates Amgen Stake in SC 13G/A Filing — SC 13G/A · 2024-01-30T00:00:00.000Z [neutral]
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 30, 2024, indicating its ownership of Amgen Inc. common stock as o
• BlackRock Amends Amgen Stake: Passive Investment Update — SC 13G/A · 2024-01-25T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended Schedule 13G/A on January 25, 2024, indicating a change in their ownership of Amgen Inc. common stock as of December 31, 2023. T